Tau Networks in Psychotic Alzheimer's Disease

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

This research project aims to understand the brain mechanisms behind the manifestation of psychotic symptoms in Alzheimer´s disease (AD), and nature of the unique relationship with tau pathology. Amongst the cognitive manifestations of psychosis are impairments related to frontal circuits (social cognition, working memory and executive function deficits). The investigator's previous work suggests a role of tau pathology (one of the hallmarks of AD neuropathology) in the manifestation of psychosis in AD. However, the cerebral mechanisms that underly this association remain poorly understood. The overarching aim of the study is is to investigate the mechanisms by which tau network pathology may promote the presentation of psychosis in AD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Maximum Age: 85
Healthy Volunteers: t
View:

• Age 65-85 years old.

• Diagnosis of probable AD dementia according to National Institute on Aging-Alzheimer's Association (NIA-AA) criteria.

• Mini-Mental State Examination (MMSE) score ≥ 10 and ≤ 26 at the screening visit.

• Clinical Dementia Rating (CDR) score ≥ 0.5.

• Logical Memory delay score of ≤8 for 16+ years of education, ≤4 for 8-15 years of education, and ≤2 for 0-7 years of education

• All the criteria for AD are met.

• Presence of one (or more) of the following symptoms:

‣ Visual or auditory hallucinations (e.g., seeing silent individuals standing in the room, seeing children in the yard, or seeing animals in the house).

⁃ Delusions (fixed false beliefs that the patient believes to be true, e.g., that the spouse is unfaithful, that possessions are being stolen, or that one is not who one claims to be).

• Age 65-85 years old.

• No known genetic risk factors for dementia.

• No cognitive complaint

• Mini-Mental State Examination (MMSE) score ≥ 26 at the screening visit.

• Logical Memory delay score of ≥9 for 16+ years of education, ≥5 for 8-15 years of education, and ≥3 for 0-7 years of education

Locations
United States
New York
The Feinstein Institutes for Medical Research
RECRUITING
Manhasset
Contact Information
Primary
Erica Christen, MS
EChriste@northwell.edu
516-562-3492
Backup
Michelle Gong, AS
MGong@northwell.edu
516-562-3492
Time Frame
Start Date: 2023-04-13
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 91
Treatments
Alzheimer's disease
* Age 65-85 years old.~* Diagnosis of probable AD dementia according to NIA-AA criteria.~* Mini-Mental State Examination (MMSE) score ≥ 10 and ≤ 26 at the screening visit.~* Clinical Dementia Rating (CDR) score ≥ 0.5.~* Logical Memory delay score of ≤8 for 16+ years of education, ≤4 for 8-15 years of education, and ≤2 for 0-7 years of education~Participants will undergo neuropsychological examination, blood collection, sensorimotor gating/ERP testing, MRI and \[18F\]-PI2620 PET scan.
Alzheimer's disease with psychosis
\- All the criteria for AD are met.~Presence of one (or more) of the following symptoms:~* Visual or auditory hallucinations (e.g., seeing silent individuals standing in the room, seeing children in the yard, or seeing animals in the house).~* Delusions (fixed false beliefs that the patient believes to be true, e.g., that the spouse is unfaithful, that possessions are being stolen, or that one is not who one claims to be).~Participants will undergo neuropsychological examination, blood collection, sensorimotor gating/ERP testing, MRI and \[18F\]-PI2620 PET scan.
Cognitively Unimpaired Healthy
Age 65-85 years old.~* No known genetic risk factors for dementia.~* No cognitive complaint~* Mini-Mental State Examination (MMSE) score ≥ 26 at the screening visit.~* Logical Memory delay score of ≥9 for 16+ years of education, ≥5 for 8-15 years of education, and ≥3 for 0-7 years of education~Participants will undergo neuropsychological examination, blood collection, sensorimotor gating/ERP testing, MRI and \[18F\]-PI2620 PET scan.
Related Therapeutic Areas
Sponsors
Leads: Northwell Health

This content was sourced from clinicaltrials.gov

Similar Clinical Trials